# A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or Obesity

> **NCT06716307** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 18 (actual)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** CagriSema (cagrilintide B and semaglutide I)
- **DRUG:** CagriSema A

## Key facts

- **NCT ID:** NCT06716307
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-12-02
- **Primary completion:** 2025-03-28
- **Final completion:** 2025-05-22
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2025-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06716307

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06716307, "A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or Obesity". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT06716307. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*